RhumbLine Advisers
BCAB icon

RhumbLine Advisers’s BioAtla BCAB Stock Holding History

RhumbLine Advisers’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-403
Closed -$27.6K – 4207
2024
Q2 		$27.6K Sell
403
-853
-68% -$101K ﹤0.01% 3814
2024
Q1 		$216K Buy
1,256
+42
+3% +$5.22K ﹤0.01% 3144
2023
Q4 		$149K Sell
1,214
-33
-3% -$2.86K ﹤0.01% 3316
2023
Q3 		$106K Buy
1,247
+72
+6% +$9.18K ﹤0.01% 3440
2023
Q2 		$176K Buy
+1,175
New +$202K ﹤0.01% 3302
2022
Q2 		– Sell
-291
Closed -$73K – 3107
2022
Q1 		$73K Buy
291
+47
+19% +$19.7K ﹤0.01% 2939
2021
Q4 		$240K Buy
244
+17
+7% +$21.7K ﹤0.01% 2782
2021
Q3 		$333K Buy
227
+17
+8% +$33.1K ﹤0.01% 2723
2021
Q2 		$445K Sell
210
-6
-3% -$13.6K ﹤0.01% 2612
2021
Q1 		$549K Buy
+216
New +$554K ﹤0.01% 2447

Other funds holding BCAB

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

RhumbLine Advisers's BCAB Position: Q3 2024 in Review

RhumbLine Advisers sold out of BioAtla (BCAB) in Q3 2024, closing a stake of 403 shares — an estimated $27.6K sold.

RhumbLine Advisers first reported a position in BCAB in Q1 2021 and held it in 10 quarters. The position peaked at $549K in Q1 2021. 63 funds tracked by Wall St. Rank hold BCAB as of Q3 2024.

  • RhumbLine Advisers reported no remaining BioAtla position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 403 BioAtla shares in Q3 2024, an estimated $27.6K.
  • RhumbLine Advisers first reported a position in BioAtla in Q1 2021 and held it in 10 quarters.
  • RhumbLine Advisers's BioAtla position peaked at $549K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held BioAtla as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.